Beyond minerals and parathyroid hormone: Role of active vitamin D in end-stage renal disease

Seminars in Dialysis

Volumn 18, Issue 4, 2005, Pages 302-306

  Wolf, Myles ^a   Thadhani, Ravi ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PARATHYROID HORMONE; VITAMIN D;

BLOOD; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; HUMAN; RENAL REPLACEMENT THERAPY; REVIEW; SECONDARY HYPERPARATHYROIDISM;

CLINICAL TRIALS; HUMANS; HYPERPARATHYROIDISM, SECONDARY; KIDNEY FAILURE, CHRONIC; PARATHYROID HORMONE; RENAL DIALYSIS; VITAMIN D;

EID: 23844456273     PISSN: 08940959     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1525-139X.2005.18406.x     Document Type: Review

References (74)

1. Ishimura E, Nishizawa Y, Inaba M, Matsumoto N, Emoto M, Kawagishi T, Shoji S, Okuno S, Kim M, Miki T, Morii H: Serum levels of 1,25-dihydroxyvitamin D, 24,25-dihydroxyvitamin D, and 25-hydroxyvitamin D in non-dialyzed patients with chronic renal failure. Kidney Int 55:1019-1027, 1999
2. Thomas MK, Lloyd-Jones DM, Thadhani RI, Shaw AC, Deraska DJ, Kitch BT, Vamvakas EC, Dick IM, Prince RL, Finkelstein JS: Hypovitaminosis D in medical inpatients. N Engl J Med 338:777-783, 1998
3. Llach F, Yudd M: Pathogenic, clinical, and therapeutic aspects of secondary hyperparathyroidism in chronic renal failure. Am J Kidney Dis 32:S3-S12, 1998
4. Fukuda N, Tanaka H, Tominaga Y, Fukagawa M, Kurokawa K, Seino Y: Decreased 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. J Clin Invest 92:1436-1443, 1993
5. Dusso AS: Vitamin D receptor: mechanisms for vitamin D resistance in renal failure. Kidney Int Suppl 85:6-9, 2003
6. Patel SR, Ke HQ, Vanholder R, Koenig RJ, Hsu CH: Inhibition of calcitriol receptor binding to vitamin D response elements by uremic toxins. J Clin Invest 96:50-59, 1995
7. Eknoyan G, Levin A, Levin NW: Bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42:1-201, 2003
8. Slatopolsky E, Weerts C, Thielan J, Horst R, Harter H, Martin KJ: Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydrocholecalciferol in uremic patients. J Clin Invest 74:2136-2143, 1984
9. Brown A, Zhong M, Finch J, Ritter C, Slatopolsky E: The roles of calcium and 1,25-dihydroxyvitamin D3 in the regulation of vitamin D receptor expression by rat parathyroid glands. Endocrinology 136:1419-1425, 1995
10. Naveh-Many T, Marx R, Keshet E, Pike JW, Silver J: Regulation of 1,25-dihydroxyvitamin D3 receptor gene expression by 1,25-dihydroxyvitamin D3 in the parathyroid in vivo. J Clin Invest 86:1965-1975, 1990
11. Naveh-Many T, Rahamimov R, Livni N, Silver J: Parathyroid cell proliferation in normal and chronic renal failure rats. J Clin Invest 96:1786-1793, 1995
12. Silver J, Sela SB, Naveh-Many T: Regulation of parathyroid cell proliferation. Curr Opin Nephrol Hypertens 6:321-326, 1997
13. Silver J, Russel J, Sherwood LM: Regulation by vitamin D metabolites of messenger ribonucleic acid for preproparathyroid hormone in isolated bovine parathyroid cells. Proc Natl Acad Sci USA 82:4270-4273, 1985
14. Gallieni M, Kamimura S, Ahmed A, Bravo E, Delmez J, Slatopolsky E, Dusso A: Kinetics of monocyte 1 alpha-hydroxylase in renal failure. Am J Physiol 268:F746-F753, 1995
15. Finch JL, Brown AJ, Slatopolsky E: Differential effects of 1,25-dihydroxyvitamin D3 and 19-nor-1,25-dihydroxy-vitamin D2 on calcium and phosphorus resorption in bone. J Am Soc Nephrol 10:980-985, 1999
16. Balint E, Marshall CF, Sprague SM: Effect of the vitamin D analogues paricalcitol and calcitriol on bone mineral in vitro. Am J Kidney Dis 36:789-796, 2000
17. Brown AJ, Finch J, Slatopolsky E: Differential effects of 19-nor-1,25-dihydroxyvitamin D(2) and 1,25-dihydroxyvitamin D(3) on intestinal calcium and phosphate transport. J Lab Clin Med 139:279-284, 2002
18. Coyne DW, Grieff M, Ahya SN, Giles K, Norwood K, Slatopolsky E: Differential effects of acute administration of 19-nor-1,25-dihydroxy-vitamin D2 and 1,25-dihydroxy-vitamin D3 on serum calcium and phosphorus in hemodialysis patients. Am J Kidney Dis 40:1283-1288, 2002
19. Llach F, Keshav G, Goldblat MV, Lindberg JS, Sadler R, Delmez J, Arruda J, Lau A, Slatopolsky E: Suppression of parathyroid hormone secretion in hemodialysis patients by a novel vitamin D analogue: 19-nor-1,25- dihydroxyvitamin D2. Am J Kidney Dis 32:S48-S54, 1998
20. Lindberg J, Martin KJ, Gonzalez EA, Acchiardo SR, Valdin JR, Soltanek C: A long-term, multicenter study of the efficacy and safety of paricalcitol in end-stage renal disease. Clin Nephrol 56:315-323, 2001
21. Martin KJ, Gonzalez EA, Gellens M, Hamm LL, Abboud H, Lindberg J: 19-Nor-1-alpha-25-dihydroxyvitamin D2 (paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis. J Am Soc Nephrol 9:1427-1432, 1998
22. Dobrez DG, Mathes A, Amdahl M, Marx SE, Melnick JZ, Sprague SM: Paricalcitol-treated patients experience improved hospitalization outcomes compared with calcitriol-treated patients in real-world clinical settings. Nephrol Dial Transplant 19:1174-1181, 2004
23. Sprague SM, Llach F, Amdahl M, Taccetta C, Batlle D: Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int 63:1483-1490, 2003
24. Block G, Hulbert-Shearon TE, Levin NW, Port FK: Association of serum phosphorus and calcium x phosphorus product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 31:607-617, 1998
25. Ganesh S, Stack AG, Levin NW, Hulbert-Shearon T, Port FK: Association of elevated PO4, Ca x PO4 product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 12:2131-2138, 2001
26. Lowrie E, Lew NL: Death risk in hemodialysis patients, the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 15:458-482, 1990
27. Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK: Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 12:2131-2138, 2001
28. Collins A, Li S, Gilbertson DT, Liu J, Chen SC, Herzog CA: Chronic kidney disease and cardiovascular disease in the Medicare population. Kidney Int 87:S24-S31, 2003
29. Brown AJ: Therapeutic uses of vitamin D analogues. Am J Kidney Dis 38:S3-S19, 2001
30. Yang S, Smith C, DeLuca HF: 1 alpha, 25-Dihydroxyvitamin D3 and 19-nor-1 alpha, 25-dihydroxyvitamin D2 suppress immunoglobulin production and thymic lymphocyte proliferation in vivo. Biochim Biophys Acta 1158:279-286, 1993
31. van Etten E, Branisteanu D, Verstuyf A, Waer M, Bouillon R, Mathieu C: Analogs of 1,25-dihydroxyvitamin D3 as dose-reducing agents for classical immunosuppressants. Transplantation 69:1932-1942, 2000
32. Moe S, Zekonis M, Harezlak J, Ambrosius WT, Gassensmith CM, Murphy CL, Russell RR, Batiuk TD: A placebo controlled trial to evaluate immunomodulatory effects of paricalcitol. Am J Kidney Dis 38:789-802, 2001
33. Xing M, Maldonado ML, Bachman LA, McKean DJ, Kumar R, Griffin MD: Distinctive dendritic cell modulation by vitamin D3 and glucocorticoid pathways. Biochem Biophys Res Commun 297:645-652, 2002
34. Timms P, Mannan N, Hitman GA, Noonan K, Mills PG, Syndercombe-Court D, Aganna E, Price CP, Boucher BJ: Circulating MMP9, vitamin D and variation in the TIMP-1 response with VDR genotype: mechanisms for inflammatory damage in chronic disorders? Q J Med 95:787-796, 2002
35. Mathieu C, Adorini L: The coming of age of 1,25-dihydroxyvitamin D3 analogs as immunomodulatory agents. Trends Mol Med 8:174-179, 2002
36. Adorini L, Penna G, Giarratana N, Uskokovic M: Tolerogenic dendritic cells induced by vitamin D receptor ligands enhance regulatory T cells inhibiting allograft rejection and autoimmune diseases. J Cell Biochem 88:227-233, 2003
37. Zella J, DeLuca HF: Vitamin D and autoimmune diabetes. J Cell Biochem 88:216-222, 2003
38. Adorini L: Immunomodulatory effects of vitamin D receptor ligands in autoimmune diseases. Int Immunopharmacol 2:1017-1028, 2002
39. Mak R: 1,25-Dihydroxyvitamin D3 corrects insulin and lipid abnormalities in uremia. Kidney Int 53:1353-1357, 1998
40. Overbergh L, Decallonne B, Waer M, Rutgeerts O, Valckx D, Casteels KM, Laureys J, Bouillon R, Mathieu C: 1alpha,25-dihydroxyvitamin D3 induces an autoantigen-specific T-helper 1/T-helper 2 immune shift in NOD mice immunized with GAD65 (p524-543). Diabetes 49:1301-1307, 2000
41. Makibayashi K, Mitsuyoshi T, Hirata M, Fukushima N, Kusano K, Ohashi S, Abe H, Kuze K, Fukatsu A, Kita T, Doi T: A vitamin D analog ameliorates glomerular injury on rat glomerulonephritis. Am J Pathol 158:1733-1741, 2001
42. Hirata M, Makibayashi K, Katsumata K, Kusano K, Watanabe T, Fukushima N, Doi T: 22-Oxacalcitriol prevents progressive glomerulosclerosis without adversely affecting calcium and phosphorus metabolism in subtotally nephrectomized rats. Nephrol Dial Transplant 17:2132-2137, 2002
43. Schwarz U, Amann K, Orth SR, Simonaviciene A, Wessels S, Ritz E: Effect of 1,25(OH)2 vitamin D3 on glomerulosclerosis in subtotally nephrectomized rats. Kidney Int 53:1696-1705, 1998
44. Slatopolsky E, Finch J, Brown A: New vitamin D analogs. Kidney Int 63:S83-S87, 2003
45. Hullet D, Cantorna MT, Redaelli C, Humpal-Winter J, Hayes CE, Sol HW, DeLuca HF: Prolongation of allografts survival by 1,25-dihydroxyvitamin D3. Transplantation 66:824-828, 1998
46. O'Herrin J, Hullett DA, Heisey DM, Sollinger HW, Becker BN: A retrospective evaluation of 1,25-dihydroxyvitamin D3 and its potential effects on renal allograft function. Am J Nephrol 22:515-520, 2002
47. Dunlap N, Schwartz GG, Eads D, Cramer SD, Sherk AB, John V, Koumenis C: 1alpha,25-dihydroxyvitamin D(3) (calcitriol) and its analogue, 19-nor-1alpha,25(OH)(2)D(2), potentiate the effects of ionising radiation on human prostate cancer cells. Br J Cancer 89:746-753, 2003
48. Tangpricha V, Flanagan JN, Whitlatch LW, Tseng CC, Chen TC, Holt PR, Lipkin MS, Holick MF: 25-hydroxyvitamin D-1alpha-hydroxylase in normal and malignant colon tissue. Lancet 357:1673-1674, 2001
49. Kumagai T, O'Kelly J, Said JW, Koeffler HP: Vitamin D2 analog 19-nor-1,25-dihydroxyvitamin D2: antitumor activity against leukemia, myeloma, and colon cancer cells. J Natl Cancer Inst 95:896-905, 2003
50. Nyomba BL, Bouillon R, De Moor P: Influence of vitamin D status on insulin secretion and glucose tolerance in the rabbit. Endocrinology 115:191-197, 1984
51. Hypponen E, Laara E, Reunanen A, Jarvelin MR, Virtanen SM: Intake of vitamin D and risk of type 1 diabetes: a birth-cohort study. Lancet 358:1500-1503, 2001
52. Kristal-Boneh E, Froom P, Harari G, Ribak J: Association of calcitriol and blood pressure in normotensive men. Hypertension 30:1289-1294, 1997
53. Scragg R, Jackson R, Holdaway IM, Lim T, Beaglehole R: Myocardial infarction is inversely associated with plasma 25-hydroxyvitamin D3 levels: a community-based study. Int J Epidemiol 19:559-563, 1990
54. Garland C, Shekelle RB, Barrett-Connor E, Criqui MH, Rossof AH, Paul O: Dietary vitamin D and calcium and risk of colorectal cancer: a 19-year prospective study in men. Lancet 1:307-309, 1985
55. Li C, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP: 1,25-Dihydroxyvitamin D3 is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 110:229-238, 2002
56. Afzali B, Bakri RS, Bharma-Ariza P, Lumb PJ, Dalton N, Turner NC, Wierzbicki AS, Crook MA, Goldsmith DJ: Raised plasma total sialic acid levels are markers of cardiovascular disease in renal dialysis patients. J Nephrol 16:540-545, 2003
57. Block GA, Martin KJ, de Francisco AL, Turner SA, Avram MM, Suranyi MG, Hercz G, Cunningham J, Abu-Alfa AK, Messa P, Coyne DW, Locatelli F, Cohen RM, Evenepoel P, Moe SM, Fournier A, Braun J, McCary LC, Zani VJ, Olson KA, Drueke TB, Goodman WG: Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 350:1516-1525, 2004
58. Lind L, Hanni A, Lithell H, Hvarfner A, Sorensen OH, Ljunghall S: Vitamin D is related to blood pressure and other cardiovascular risk factors in middle-aged men. Am J Hypertens 8:894-901, 1995
59. Resnick L, Muller B, Laragh JH: Calcium-regulating hormones in essential hypertension. Ann Intern Med 105:649-654, 1986
60. Wu J, Garami M, Cheng T, Gardner DG: 1,25(OH)2 vitamin D3 and retinoic acid antagonize endothelin-stimulated hypertrophy of neonatal rat cardiomyocytes. J Clin Invest 97:1577-1588, 1996
61. O'Connell T, Berry JE, Jarvis AK, Somerman MJ, Simpson RU: 1,25-Dihydroxyvitamin D3 regulation of cardiac myocyte proliferation and hypertrophy. Am J Physiol 272:H1751-H1758, 1997
62. Watson KE, Abrolat ML, Malone LL: Active serum vitamin D levels are inversely correlated with coronary calcification. Circulation 96:1755-1760, 1997
63. Zittermann A, Schleithoff SS, Tenderich G, Berthold HK, Korfer R, Stehle P: Low vitamin D status: a contributing factor in the pathogenesis of congestive heart failure? J Am Coll Cardiol 41:105-112, 2003
64. Park CW, Oh YS, Shin YS, Kim CM, Kim YS, Kim SY, Choi EJ, Chang YS, Bang BK: Intravenous calcitriol regresses myocardial hypertrophy in hemodialysis patients with secondary hyperparathyroidism. Am J Kidney Dis 33:73-81, 1999
65. Foley R, Parfrey PS, Sarnak MJ: Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 32:S112-S119, 1998
66. Knight EL, Ofsthun N, Teng M, Lazarus JM, Curhan GC: The association between mental health, physical function, and hemodialysis mortality. Kidney Int 63:1843-1851, 2003
67. Thadhani R, Wolf M, Ofsthun MN, Lazarus JM, Camargo CA Jr, Teng M: Hemodialysis survival and vitamin D injections: a historical cohort study. J Am Soc Nephrol 15:188A, 2004
68. Rostand SG, Drueke TB: Parathyroid hormone, vitamin D, and cardiovascular disease in chronic renal failure. Kidney Int 56:383-392, 1999
69. Shoji T, Shinohara K, Kimoto E, Emoto M, Tahara H, Koyama H, Inaba M, Fukumoto S, Ishimura E, Miki T, Tabata T, Nishizawa Y: Lower risk for cardiovascular mortality in oral 1alpha-hydroxy vitamin D3 users in a haemodialysis population. Nephrol Dial Transplant 19:179-184, 2004
70. Block GA, Port FK: Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management. Am J Kidney Dis 35:1226-1237, 2000
71. Mallick NP, Berlyne GM: Arterial calcification after vitamin-D therapy in hyperphosphatemic renal failure. Lancet 2:1316-1320, 1968
72. Cunningham J: What is the optimal regimen for vitamin D? Kidney Int Suppl 73:S59-S64, 1999
73. Quinibi WY, Nolan CA, Ayus JC: Cardiovascular calcification in patients with end-stage renal disease: a century-old phenomenon. Kidney Int Suppl 82:73-80, 2002
74. Ritz E, Schomig M, Bommer J: Osteodystrophy in the millennium. Kidney Int Suppl 73:S94-S98, 1999